About: Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak
Creator	Liu, Lei Zhang, Zheng Cai, Yi Hu, Yunlong Chen, Xinchun Dai, Youchao Guo, Jiubiao Huang, Kaisong Lin, Dachuan Xu, Yuzhong Yang, Qianting Zhang, Mingxia
Source	Medline; PMC
abstract	We developed a chemiluminescence immunoassay method based on the recombinant nucleocapsid antigen and assessed its performance for the clinical diagnosis of severe acute respiratory syndrome coronavirus (SARS-CoV)-2 infections by detecting SARS-CoV-2–specific IgM and IgG antibodies in patients. Full-length recombinant nucleocapsid antigen and tosyl magnetic beads were used to develop the chemiluminescence immunoassay approach. Plasmas from 29 healthy cohorts, 51 tuberculosis patients, and 79 confirmed SARS-CoV-2 patients were employed to evaluate the chemiluminescence immunoassay method performance for the clinical diagnosis of SARS-CoV-2 infections. A commercial ELISA kit (Darui Biotech, China) using the same nucleocapsid antigen was used for the in-parallel comparison with our chemiluminescence immunoassay method. The IgM and IgG manner of testing in the chemiluminescence immunoassay method showed a sensitivity and specificity of 60.76% (95% CI 49.1 to 71.6) and 92.25% (95% CI 83.4 to 97.2) and 82.28% (95% CI 72.1 to 90.0) and 97.5% (95% CI 91.3 to 99.7), respectively. Higher sensitivity and specificity were observed in the chemiluminescence immunoassay method compared with the Darui Biotech ELISA kit. The developed high sensitivity and specificity chemiluminescence immunoassay IgG testing method combined with the RT-PCR approach can improve the clinical diagnosis for SARS-CoV-2 infections and thus contribute to the control of COVID-19 expansion. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10096-020-03978-6) contains supplementary material, which is available to authorized users.
has issue date	2020-07-17(xsd:dateTime)
bibo:doi	10.1007/s10096-020-03978-6
bibo:pmid	32681308
has license	no-cc
sha1sum (hex)	adf437c79b8cff7ae0716548edfdaacea41f4aa9
schema:url	https://doi.org/10.1007/s10096-020-03978-6
resource representing a document's title	Evaluations of the serological test in the diagnosis of 2019 novel coronavirus (SARS-CoV-2) infections during the COVID-19 outbreak
has PubMed Central identifier	PMC7367508
has PubMed identifier	32681308
schema:publication	Eur J Clin Microbiol Infect Dis
resource representing a document's body	covid:adf437c79b8cff7ae0716548edfdaacea41f4aa9#body_text
is schema:about of	named entity '95% CI' named entity 'SARS-CoV-2' named entity 'compared' named entity 'IgG' named entity 'chemiluminescence' named entity 'diagnosis' named entity 'BASED' named entity 'ANTIGEN' named entity 'USED' named entity 'COMPARISON' named entity 'LENGTH' named entity 'OUR' named entity 'APPROACH' named entity 'HEALTHY' named entity 'COMBINED' named entity 'ANTIBODIES' named entity 'EXPANSION' named entity '97.2' named entity 'infections' named entity 'testing' named entity 'chemiluminescence' named entity 'diagnosis' named entity 'China' named entity 'severe acute respiratory syndrome coronavirus' named entity 'SARS-CoV-2' named entity 'evaluate' named entity 'control' named entity 'chemiluminescence' named entity 'IgG' named entity 'Plasmas' named entity 'chemiluminescence' named entity 'antigen' named entity 'sensitivity and specificity' named entity 'SARS-CoV-2' named entity '95% CI' named entity 'China' named entity 'sensitivity and specificity' named entity 'immunoassay' named entity '95% CI' named entity 'developed' named entity 'molecular biologic' named entity 'antigens' named entity 'tuberculosis' named entity 'SARS-CoV-2' named entity 'China' named entity 'Betacoronavirus' named entity 'immunoglobulin' named entity 'Betacoronavirus' named entity 'confounding factor' named entity 'SARS-CoV-2' named entity 'MERS-CoV' named entity 'IgM' named entity 'antigens' named entity 'SARS-CoV-2' named entity 'RT-PCR' named entity '95% CI' named entity 'IgM' named entity 'immunoassay' named entity 'Shenzhen' named entity 'severe acute respiratory syndrome coronavirus' named entity 'bronchoalveolar lavage fluid' named entity 'IgG' named entity 'microscopic analysis' named entity 'RT-PCR' named entity 'antibodies' named entity 'receiver operating characteristic' named entity 'coronavirus' named entity 'nucleic acid' named entity 'Shenzhen' named entity 'immunoassay'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software